Stanford identifies natural peptide cutting food intake by 50%

Existing GLP-1 receptor agonists present a known metabolic dilemma. While they consistently lower body weight, patient data shows up to 40% of the lost tissue can be skeletal muscle rather than adipose tissue, alongside persistent gastrointestinal effects that lead roughly half of users to discontinue treatment within one year.

Stanford University researchers screened biological libraries to locate alternative signaling candidates, identifying a natural peptide designated BRP. In animal trials, the compound reduced daily food intake by up to 50% while promoting adipose loss. Crucially, the compound spared lean tissue and bypassed the common nausea responses observed with typical receptor agonists.

Rather than stimulating standard gut-brain satiety axes, BRP targets distinct neural receptors in the hypothalamus. This functional divergence explains why the test subjects avoided digestive distress. Computational screening models sorted through millions of molecular structures to surface this target sequence, compressing what historically took a decade of wet-lab screening into months.

Human clinical trials will determine whether this mechanism translates safely to human biology. Until human pharmacokinetic data is published, focus on verifiable habits that preserve metabolic rate: track your daily protein intake against resistance training metrics, rather than chasing speculative compounds ahead of peer-reviewed safety evidence.